Association between the functional FCGR3A F158V and FCGR2A R131H polymorphisms and responsiveness to biologics in rheumatoid arthritis patients: A meta‐analysis
International Journal of Rheumatic Diseases · 2023
DOI: 10.1111/1756-185x.14719 ↗Kurz gefasst
Metaanalyse in der Zeitschrift International Journal of Rheumatic Diseases, 2023. Verfasst von Young Ho Lee und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Korea University Medicine, Seoul, South Korea. Hauptthemen laut MEDLINE: Biological Products, Arthritis, Rheumatoid, Antineoplastic Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 44 Literaturangaben.
Abstract (Originalsprache)
Objectives
This study aimed to investigate the association between functional Fc gamma receptor 3A ( FCGR3A ) V158F and FCGR2A R131H polymorphisms and biologic therapy in rheumatoid arthritis (RA) patients.
Methods
We searched Medline, Embase, and Cochran databases for available articles. This study is a meta‐analysis of the association between the FCGR3A V158F and FCGR2A R131H polymorphisms and their responsiveness to biologics in RA patients.
Results
Seventeen studies involving RA patients with FCGR3A V158F ( n = 1884) and FCGR2A R131H ( n = 1118) polymorphisms were considered. This meta‐analysis showed that the FCGR3A V allele was associated with responsiveness to rituximab (odds ratio [OR] = 1.431, 95% CI = 1.081–1.894, P = 0.012), but not with tumor necrosis factor (TNF) blockers, tocilizumab, or abatacept. A significant association was also found between the FCGR3A V158F polymorphism and responsiveness to biologics using the dominant‐recessive model. Additionally, the FCGR3A V158F polymorphism was associated with responsiveness to TNF blockers in the homozygous contrast model. Meta‐analysis revealed an association between the FCGR2A RR + RH genotype and responsiveness to biologics (OR = 1.385, 95% CI = 1.007–1.904, P = 0.045).
Conclusions
This meta‐analysis demonstrates that FCGR3A V allele carriers show better responsiveness to rituximab, and FCGR2A R allele carriers may show a better response to biologics in RA treatment. Genotyping of these polymorphisms could be a useful tool to find associations with the responsiveness of personalized medicine to biologics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology, Korea University Medicine, Seoul, South Korea.
ORCID-Profile: Young Ho Lee
Zitieren
APA
Lee, Y. H., & Song, G. G. (2023). Association between the functional FCGR3A F158V and FCGR2A R131H polymorphisms and responsiveness to biologics in rheumatoid arthritis patients: A meta‐analysis. International Journal of Rheumatic Diseases. https://doi.org/10.1111/1756-185x.14719
Vancouver
Lee YH, Song GG. Association between the functional FCGR3A F158V and FCGR2A R131H polymorphisms and responsiveness to biologics in rheumatoid arthritis patients: A meta‐analysis. International Journal of Rheumatic Diseases. 2023. doi:10.1111/1756-185x.14719
BibTeX
@article{Lee2023,
author = {Lee, Young Ho and Song, Gwan Gyu},
title = {Association between the functional FCGR3A F158V and FCGR2A R131H polymorphisms and responsiveness to biologics in rheumatoid arthritis patients: A meta‐analysis},
journal = {International Journal of Rheumatic Diseases},
year = {2023},
doi = {10.1111/1756-185x.14719}
}
EUVIMED